Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes

Inflammation

Volumn 36, Issue 4, 2013, Pages 888-896

  Li, Minghui ^a   Liu, Xu ^a   Sun, Xiaolin ^a   Wang, Zhenhua ^b   Guo, Weikang ^b   Hu, Fanlei ^a   Yao, Haihong ^a   Cao, Xuefeng ^b   Jin, Jin ^b   Wang, Peng G ^b   Shen, Jie ^b   Li, Zhanguo ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

collagen induced arthritis (CIA); fibroblast like synoviocytes (FLSs); histone deacetylase inhibitor (HDACi); rheumatoid arthritis (RA)

Indexed keywords

3 [1 [1 (BENZO[D]OXAZOL 2 YL) 2 METHYLPROPYL] 1H 1,2,3 TRIAZOL 4 YL] N HYDROXYACRYLAMIDE; CASPASE; COLLAGEN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SUBCROYLANILIDE HYDROXAMIC ACID; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; FIBROBLAST LIKE SYNOVIOCYTE; FLOW CYTOMETRY; FLUORESCENCE; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; M PHASE CELL CYCLE CHECKPOINT; MALE; MOUSE; NONHUMAN; ONSET AGE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIGNAL TRANSDUCTION; SYNOVIOCYTE; THERAPY EFFECT; TREATMENT DURATION;

ANIMALS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; BENZOXAZOLES; CASPASE 3; CASPASE 8; CASPASE 9; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CYTOKINES; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INFLAMMATION; MALE; MICE; MICE, INBRED DBA; MIDDLE AGED; SYNOVIAL MEMBRANE;

MUS;

EID: 84880283454     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9616-0     Document Type: Article

References (17)

1. Scott, D.L.; F. Wolfe, and T.W. Huizinga. 2010. Rheumatoid arthritis. Lancet 376: 1094-1108.
2. Lefevre, S.; A. Knedla, C. Tennie, A. Kampmann, C. Wunrau, R. Dinser, A. Korb, E.M. Schnaker, I.H. Tarner, P.D. Robbins, C.H. Evans, H. Sturz, J. Steinmeyer, S. Gay, J. Scholmerich, T. Pap, U. Muller-Ladner, and E. Neumann. 2009. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15: 1414-1420.
3. Feldmann, M.; F.M. Brennan, and R.N. Maini. 1996. Rheumatoid arthritis. Cell 85: 307-310.
4. van der Linden, M.P.; D. van der Woude, A. Ioan-Facsinay, E.W. Levarht, G. Stoeken-Rijsbergen, T.W. Huizinga, R.E. Toes, and A.H. van der Helm-van Mil. 2009. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 60: 2232-2241.
5. Choo, Q.Y.; P.C. Ho, and H.S. Lin. 2008. Histone deacetylase inhibitors: New hope for rheumatoid arthritis? Curr Pharm Des 14: 803-820.
6. Grabiec, A.M.; P.P. Tak, and K.A. Reedquist. 2008. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: Should we keep our HATs on? Arthritis Res Ther 10: 226.
7. Lin, H.S.; C.Y. Hu, H.Y. Chan, Y.Y. Liew, H.P. Huang, L. Lepescheux, E. Bastianelli, R. Baron, G. Rawadi, and P. Clement-Lacroix. 2007. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150: 862-872.
8. Saouaf, S.J.; B. Li, G. Zhang, Y. Shen, N. Furuuchi, W.W. Hancock, and M.I. Greene. 2009. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 87: 99-104.
9. Hou, J.; Z. Li, Q. Fang, C. Feng, H. Zhang, W. Guo, H. Wang, G. Gu, Y. Tian, P. Liu, R. Liu, J. Lin, Y.K. Shi, Z. Yin, J. Shen, and P.G. Wang. 2012. Discovery and extensive in vitro evaluations of NK-HDAC-1: A chiral histone deacetylase inhibitor as a promising lead. J Med Chem 55: 3066-3075.
10. Arnett, F.C.; S.M. Edworthy, D.A. Bloch, D.J. McShane, J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Liang, H.S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
11. Reisch, N.; A. Engler, A. Aeschlimann, B.R. Simmen, B.A. Michel, R.E. Gay, S. Gay, and H. Sprott. 2008. DREAM is reduced in synovial fibroblasts of patients with chronic arthritic pain: Is it a suitable target for peripheral pain management? Arthritis Res Ther 10: R60.
12. Kim, W.U.; W.K. Lee, J.W. Ryoo, S.H. Kim, J. Kim, J. Youn, S.Y. Min, E.Y. Bae, S.Y. Hwang, S.H. Park, C.S. Cho, J.S. Park, and H.Y. Kim. 2002. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: A novel treatment strategy for induction of oral tolerance. Arthritis Rheum 46: 1109-1120.
13. Nishikawa, M.; A. Myoui, T. Tomita, K. Takahi, A. Nampei, and H. Yoshikawa. 2003. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 48: 2670-2681.
14. Carafa, V.; M. Miceli, L. Altucci, and A. Nebbioso. 2013. Histone deacetylase inhibitors: A patent review (2009-2011). Expert Opin Ther Pat 23: 1-17.
15. Bartok, B.; and G.S. Firestein. 2010. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol Rev 233: 233-255.
16. Kandasamy, K.; S.M. Srinivasula, E.S. Alnemri, C.B. Thompson, S.J. Korsmeyer, J.L. Bryant, and R.K. Srivastava. 2003. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: Differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 63: 1712-1721.
17. Hancock, W.W.; T. Akimova, U.H. Beier, Y. Liu, and L. Wang. 2012. HDAC inhibitor therapy in autoimmunity and transplantation. Ann Rheum Dis 71(Suppl 2): i46-i54.